Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
HIV is spread by bodily fluids such as blood, breast milk or semen. It gradually weakens the body’s immune system and makes ...
Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...
However, the overall costs and consequences of these recommendations ... For example, if someone is injecting drugs, is given an opt-out HIV test, but is never questioned about substance use ...
A change in Medicare policy is expected to flatten revenue from Gilead Science's HIV products, one of its most profitable segments.
For treating HIV, Descovy and Truvada are taken with ... For other resources that might help you save on the price of these drugs, see the Descovy cost article and Truvada cost article.
She is now enrolled in a drug trial for a promising PrEP injection but worries about future access and cost. Preexposure prophylaxis, known as PrEP, reduces the risk of new HIV infections through ...